Physician profile
Ann E Piscitelli
NPI 1730285206
$3,434.74
in general payments reported to CMS, 2019-2025
25 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.14 · 2020: $123 · 2021: $557 · 2022: $699 · 2023: $556 · 2024: $683 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $519.72 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $495.85 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $386.92 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $338.97 | 2021-2024 | |
| Lilly USA, LLC | $270.59 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Cleerly, INC. | $214.14 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Exact Sciences Corporation | $185.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.18 | 2021-2025 | Xifaxan |
| Boston Scientific Corporation | $162.58 | 2022-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.08 | 2021-2023 | Spevigo |
| Abbvie INC. | $102.23 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.54 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $61.21 | 2021-2022 | |
| Novo Nordisk INC | $60.21 | 2024-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $44.55 | 2024-2025 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.15 | 2025 | |
| Merck Sharp & Dohme LLC | $30.29 | 2021-2025 | Capvaxive |
| Corcept Therapeutics | $25.61 | 2025 | Korlym |
| Astellas Pharma US INC | $24.37 | 2023 | Veozah |
| Amarin Pharma, INC. | $18.52 | 2021 | |
| Sanofi Pasteur INC. | $18.20 | 2023 | |
| Shionogi INC | $17.32 | 2021 | |
| Philips North America LLC | $17.20 | 2023 | |
| Idorsia Pharmaceuticals US INC | $12.95 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Piscitelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.